Recce Pharmaceuticals Secures Global Patent Protection for Anti-Infectives, Paving the Way for Novel Antibiotic Solutions
Recce Pharmaceuticals Ltd., a clinical-stage biotechnology company, announced it has secured global patent protection for its triad of innovative synthetic anti-infectives. The final patent in Family 3 granting the company IP protection across all major pharmaceutical markets globally.
Australia’s Patent Office has formally granted the latest patent, building upon Recce Pharmaceuticals’ expanding global intellectual property portfolio.
World-Class Patent Protection for Next-Generation Anti-Infectives
This latest patent grant signifies a major milestone for Recce, validating its pioneering synthetic anti-infective technology. “We are thrilled by the Australian Patent Office’s recognition of the groundbreaking potential of our new class of anti-infectives,” said James Graham, CEO of Recce Pharmaceuticals. These patents solidify our global intellectual property portfolio, providing exclusive rights to R327 and R529 in all leading pharmaceutical markets until 2037. The expected expiry of 2037 protects Recce medicines through early access to treat urgent global health problems of antibiotic-resistant superbugs”. This milestone exemplifies our dedication to addressing critical viral threats with innovative therapies and ensures we are well-positioned to deliver impactful solutions for patients worldwide.”
The Australian patent, similar to previously granted patents in other major markets, reinforces Recce’s competitive edge in the fight against antimicrobial resistance. With world-leading manufacturing in place for its banner compounded and ready for commercialization
Fighting Against the Threat of Antimicrobial Resistance
Recce’s anti-infective pipeline comprises three patented, Conquer bacterial infections.</ylated
Recce Pharmaceuticals is focused on addressing unmet medical needs with antibacterial agents, focusing on fighting antibiotic-resistant pathogens. R327, R435 and R529, their synthetic anti-infectives, distinct approaches to combat these global threats.
The World Health Organization included R327, R435, and R529 on its list of antibacterial products in clinical development for priority pathogens, highlighting Recce’s dedication to battling antimicrobial resistance. R327 received Qualified Infectious Disease Product solicitation under the Generating Antibiotic Initiatives Now (GAIN) Act, granting Fast Track Designation and 10 years of exclusivity upon approval. R327 is also designated for orphan ideals for the development of novel tracing therapeutics.
https://www.reccepharmaceuticals.com/
Cocce’s wholly owned automated manufacturing supports clinical trials.
### Recce Pharmaceuticals: Pioneers in the Fight Against Antimicrobial Resistance
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of synthetic anti-infectiveslecce R529
Copyright laws, the company’s pipeline represents a potentially groundbreaking tools against a rangehe formidable rise of antimicrobial resistance.
What are the next steps in the clinical development of RECCE® R327 and R529?
## A Breakthrough in Antibiotic Development: An Interview with Recce Pharmaceuticals CEO James Graham
**Interviewer:** Welcome to the show, Mr. Graham. Congratulations on Recce Pharmaceuticals securing global patent protection for your innovative synthetic anti-infectives. This is a major accomplishment.
**James Graham:** Thank you. We’re thrilled to have reached this milestone. It underscores the potential of our technology to address the growing global threat of antibiotic resistance.
**Interviewer:** Can you tell our viewers a little bit about your new class of anti-infectives and what makes them so groundbreaking?
**James Graham:** Absolutely. Our RECCE® anti-infectives represent a completely novel approach. They are synthetically derived, meaning we can precisely design them to target specific pathogens while minimizing the risk of resistance development. This contrasts with traditional antibiotics, which are often derived from natural sources and face increasing resistance.
**Interviewer:** And this global patent protection you’ve secured, what does that mean for Recce Pharmaceuticals and for patients worldwide?
**James Graham:** This patent protection grants us exclusive rights to commercialize RECCE® R327 and R529 in all major pharmaceutical markets until 2037 [[1](https://www.einnews.com/pr_news/764285304/recce-pharmaceuticals-granted-australia-patent-for-recce-anti-infectives)]. This provides long-term certainty for our development and ensures we can bring these life-saving solutions to patients who desperately need them.
**Interviewer:** You mentioned addressing the global threat of antibiotic resistance. How do you see RECCE® technology playing a role in combating this crisis?
**James Graham:** Antibiotic resistance is one of the most pressing health challenges of our time. Our technology has the potential to be a game-changer. Because our anti-infectives are synthetically designed,
they are less likely to trigger resistance. This means they could help preserve the effectiveness of existing antibiotics and provide a new weapon against deadly superbugs.
**Interviewer:** Where does Recce Pharmaceuticals go from here? What are the next steps in bringing these anti-infectives to market?
**James Graham:** We have a robust clinical development program underway and are advancing RECCE® R327 and R529 through clinical trials. We anticipate exciting progress in the coming months as we move toward regulatory approval. Our goal is to deliver these innovative solutions to patients as quickly as possible.
**Interviewer:** Thank you, Mr. Graham, for sharing these exciting developments with us. We wish you and Recce Pharmaceuticals continued success in your important mission.
